Alemtuzumab
CMV infection?
Disability improvement
Anti-CD20s (ocrelizumab, ofatumumab, rituximab, ublituximab)
Q&A 175: which anti-CD20 is best for me?
Q&A 168 – Is it a relapse on ofatumumab?
Q&A 159: breastfeeding on ocrelizumab
Q&A 92: shingles on ocrelizumab
Serious infections on anti-CD20 therapies
Cladribine
Q&A 165: irradiated blood after cladribine
Fumarates (dimethyl fumarate and diroximel fumarate)
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
Q&A 69: Inflammatory bowel disease and MS
Glatiramer acetate (GA)
Case study: Copaxone, menstruation and the menopause
HSCT (Haematopoietic stem cell transplant)
Interferon-beta (IFN-beta)
Case study: does treating MS early improve survival?
Disability improvement
Mitoxantrone
Natalizumab
S1P modulators (fingolimod, siponimod, ozanimod, ponesimod)
New Hope for Preserving Mobility: How Siponimod May Delay Wheelchair Use in SPMS
Teriflunomide
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
Tolebrutinib (not yet licensed widely)
Tolebrutinib licensed by the EU for treating non-relapsing SPMS (April 2026)
Tolebrutinib treatment algorithm 2.0 – January 27, 2026
Proposed tolebrutinib treatment algorithm – January 26, 2026
Tolebrutinib PPMS trial is negative (December 2025)